Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TNFRSF11B is a member of the TNF-receptor superfamily. Additionally we are shipping Tumor Necrosis Factor Receptor Superfamily, Member 11b Antibodies (173) and Tumor Necrosis Factor Receptor Superfamily, Member 11b Kits (80) and many more products for this protein.
Showing 10 out of 41 products:
Mouse (Murine) TNFRSF11B Protein expressed in HEK-293 - ABIN2666866
Boyce, Xing: Biology of RANK, RANKL, and osteoprotegerin. in Arthritis research & therapy 2007
Show all 7 references for 2666866
Human TNFRSF11B Protein expressed in HEK-293 Cells - ABIN2181847
Tsuda, Goto, Mochizuki, Yano, Kobayashi, Morinaga, Higashio: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. in Biochemical and biophysical research communications 1997
Show all 4 references for 2181847
Human TNFRSF11B Protein expressed in Human Cells - ABIN2002484
Simonet, Lacey, Dunstan, Kelley, Chang, Lüthy, Nguyen, Wooden, Bennett, Boone, Shimamoto, DeRose, Elliott, Colombero, Tan, Trail, Sullivan, Davy, Bucay, Renshaw-Gegg, Hughes, Hill, Pattison, Campbell et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. ... in Cell 1997
Show all 4 references for 2002484
Rhesus Monkey TNFRSF11B Protein expressed in Human Cells - ABIN2009907
Yasuda, Shima, Nakagawa, Mochizuki, Yano, Fujise, Sato, Goto, Yamaguchi, Kuriyama, Kanno, Murakami, Tsuda, Morinaga, Higashio: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. in Endocrinology 1998
Show all 4 references for 2009907
Physical activity does not increase circulating osteoprotegerin level.
OPG may be a potential driver of lung cancer cells and therefore might have potential in therapy and diagnostics.
our findings suggest OPG is a downstream effector of IL1B (show IL1B Proteins)-mediated invasion in breast cancer cells.
measurement of serum osteoprotegerin concentration might be useful as a surrogate marker for determining bone loss in patients with chronic kidney disease, especially for women, although not so much for men.
In patients with tightly controlled rheumatoid arthritis, serum OPG was inversely associated with progression of joint destruction.
estrogen may post-transcriptionally regulate OPG expression through suppression of miR (show MLXIP Proteins)-145 expression.
TNFRSF11B mutation is associated with Juvenile Paget's disease.
Review: OPG, RANKL (show TNFSF11 Proteins) and TRAIL are involved in vascular calcification.
we report the involvement of OPG in cellular and molecular changes in MVP (show MVP Proteins) isolated cells. In addition, we detected elevated circulating OPG levels in MVP (show MVP Proteins) patients when compared to controls, which supports the hypothesis that OPG is involved in MVP (show MVP Proteins) development and progression.
Our results suggest that the polymorphism of the RANKL (show TNFSF11 Proteins), RANK, and OPG genes does not make a significant genetic contribution to heel ultrasound measurements in a population of young Caucasian adults. Further studies replicating the results in independent populations are needed to support these initial findings.
RANK/RANKL (show TNFSF11 Proteins) signaling is involved in the androgen deprivation therapy-induced acceleration of bone metastasis in castration-insensitive prostate cancer and is inhibited by osteoprotegerin to prevent bone metastasis.
endocortical resorption is driven by reduced OPG (show TNFSF11 Proteins) rather than elevated RANKL (show TNFSF11 Proteins) expression
Diabetes significantly increased OPG (show TNFSF11 Proteins) and the OPG (show TNFSF11 Proteins)/TRAIL ratio expression in the aorta, while dyslipidemia was the major determinant of the changes observed in the heart, where it significantly increased OPG (show TNFSF11 Proteins) and reduced TRAIL expression, thus increasing cardiac OPG (show TNFSF11 Proteins)/TRAIL ratio.
These discoveries strongly suggest that Heparan Sulfate plays an active role in regulating OPG-RANKL (show TNFSF11 Proteins) interaction and osteoclastogenesis.
OPG (show TNFSF11 Proteins) plays an important role in regulating bone marrow mesenchymal stem cells differentiation and bone marrow adipogenesis.
These data suggested that OPG (show TNFSF11 Proteins) played an important role in maintaining the homeostasis of articular cartilage of femoral head.
Data show that p38alpha (show MAPK14 Proteins) mitogen-activated protein kinase (show MAPK1 Proteins) (MAPK (show MAPK1 Proteins)) in paired related homeobox 1 (show PRRX1 Proteins) protein (Prx1 (show PRDX1 Proteins)+) bone marrow-derived mesenchymal stromal cells acts to preserve the bone by sustaining osteoprotegerin (OPG) production.
OPG (show TNFSF11 Proteins) expression in chondrocyte increases bone mass in the proximal metaphysis of tibiae through negative regulation of osteoclast formation.
the generation of Rag2GFP+ regulatory T cells is unaltered in Tnfrsf11b(-/-) mice
identify osteoprotegerin as a HIF target gene capable of directing osteoblast-mediated osteoclastogenesis to regulate bone homeostasis
The OPG (show TNFSF11 Proteins) expression levels decreased while those of RANKL (show TNFSF11 Proteins) and RUNX2 (show RUNX2 Proteins) increased during orthodontic tooth movement, which suggested that they play a role in the osteogenesis process and the reconstruction of periodontal tissue.
Low-frequency vibration may promote the osteogenic differentiation capability of BMSC probably through regulating the OPG/RANKL (show TNFSF11 Proteins) mRNA expression.
Regional variation of periosteal activity at the mandibular ramus is regulated by differential expression of osteoprotegerin.
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis (By similarity).
osteoclastogenesis inhibitory factor
, tumor necrosis factor receptor superfamily member 11B
, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
, tumor necrosis factor receptor superfamily, member 11b
, tumor necrosis factor receptor superfamily member 11B-like